Coegin Pharma provides NPP-4 development update - INCI registration filed and commercialization preparations on track.
Coegin Pharma AB ("Coegin" or the "Company") today provides an update on the development of NPP-4, the Company's next-generation cosmetic peptide innovation designed to enhance s...
REG
Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)
Today, on May 21, 2026, the Annual General Meeting of Coegin Pharma AB (publ) ("Coegin Pharma" or the "Company") was held. A summary of the resolutions adopted follows below. All...
REG
Coegin Pharma AB publishes its interim report for the first quarter of 2026
Summary of interim reportThe first quarter of 2026 marked Coegin Pharma's transition from initial launch to commercial scale-up, with first commercial revenues from Follicopeptid...
Coegin Pharma's partner Mercapharm prepares major commercial launch of Follicopeptide® in Poland
Coegin Pharma AB ("Coegin" or the "Company") today announces that its Polish partner Mercapharm is preparing the commercial launch of Trichobalance, Mercapharm's new premium bran...
REG
Coegin Pharma AB publishes Annual Report for 2025
Coegin Pharma AB ("Coegin" or the "Company") today announces that the Annual Report for 2025 is available on the Company's website, www.coeginpharma.com, and is also attached to...
REG
Kallelse till årsstämma i Coegin Pharma AB (publ)
Aktieägarna i Coegin Pharma AB kallas härmed till årsstämma torsdagen den 21 maj 2026 kl. 10.00 på Medicon Village, Scheeletorget 1, i Lund.
Rätt att delta och anmälan Aktieägare...
REG
Notice of annual general meeting in Coegin Pharma AB (publ)
The shareholders of Coegin Pharma AB are hereby invited to attend the Annual General Meeting on Thursday, 21 May 2026 at 10:00 a.m. at Medicon Village, Scheeletorget 1, Lund.
Rig...
Coegin Pharma expands commercial strategy with own-brand distribution model - launches VEXIENNE®
Coegin Pharma AB ("Coegin" or the "Company") today announces the expansion of its commercial strategy through the introduction of an own-brand distribution model for its Follicop...
Coegin Pharma's management acquires shares in the company
Coegin Pharma AB today announces that the company's CEO, CFO and CMO have acquired additional shares in the company.
CEO Jens Eriksson has acquired 24,293 shares, CFO Lars Bukhav...
Coegin Pharma receives first purchase order for new scalp serum
Coegin Pharma AB ("Coegin" or the "Company") today announces that it has received its first limited purchase order for the Company's newly introduced high-performance cosmetic sc...
Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum
Coegin Pharma AB ("Coegin") today announces further details on the launch of a new high-performance cosmetic scalp serum developed to optimize the scalp environment. The product...
REG
Coegin Pharma AB (publ) publishes its year-end report for 2025
Summary of year-end report 2025With products on the market, strengthened financing and a growing platform strategy, Coegin Pharma enters 2026 from a significantly stronger positi...
REG
MAR
Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position
The Board of Directors of Coegin Pharma AB (publ) (the "Company" or "Coegin Pharma") has today resolved to carry out directed issues totalling up to approximately SEK 12.1 millio...
Coegin Pharma provides an operational and strategic update
Coegin Pharma AB ("Coegin" or the "Company") today provides an operational and strategic update regarding its commercialization activities and business planning.
Operational upda...
Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor
Coegin Pharma AB ("Coegin") is delighted to announce that Professor Desmond J. Tobin, a globally recognized leader in skin and hair pigmentation science and hair-follicle biology...
Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken
Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has completed its first commercial delivery of hair growth products based on Follicopeptide® to Hårk...
Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents
Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has successfully produced and delivered its first commercial batch of hair growth products based on...
REG
Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting
The Nomination Committee of Coegin Pharma has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on May 22, 2025....
Om Coegin Pharma
Coegin Pharma är ett svenskt innovationsbolag som utvecklar och kommersialiserar avancerade kosmetiska teknologier för hår och hud.
Webbplats
www.coeginpharma.com
Bransch
Bioteknik
Prenumerera
Få löpande information från Coegin Pharma via e-post.
Handelsinformation
Kurs 3,84 SEK (2026-06-05)
Förändring 7,26% (2025-06-05)